HLA-A*02 is the most prevalent and polymorphic major histocompatibility complex (MHC) allele family in humans. Functional differences have been revealed among subtypes, demanding further subtyping of HLA-A*02 in basic and clinical settings. However, the fast growing polymorphisms render traditional primer-or probe-based typing methods impractical and result in increasing ambiguities in direct sequence-based typing. In this study, we combined group-specific amplification and mono-allelic sequencing to design and validate a simple scheme for the complete screening and accurate subtyping of all 540 reported HLA-A*02 alleles. This scheme could be performed in routine labs to facilitate studies with an interest in HLA-A*02.
INTRODUCTION
HLA-A*02 (A*02) is the most prevalent major histocompatibility complex (MHC) class I allele family in humans, presenting at high frequencies in all ethnic populations. 1 However, A*02 is the most polymorphic MHC allele family identified, with 540 alleles, and an additional allele A*02:415, recorded in the IMGT/HLA database (release 3.12.0). 2 Early studies have established that even a single amino-acid difference in the peptide-binding groove of the A*02 molecule might be sufficient to dramatically change the nature of bound peptides. 3, 4 A recent study of the crystal structures of three A*02 alleles revealed that minor residue changes between different alleles induce significant alterations in the MHC-peptide interface and introduce conformational changes in the p3-p8 peptide region. 5 Structural and functional differences underlie the differential disease outcome in individuals of different A*02 subtypes, 6 and there is a need for high-resolution A*02 subtyping of individuals for the design of personalized vaccines and the development of disease treatments. 7 A number of DNA-based techniques have been used for HLA typing, and the most commonly used techniques include polymerase chain reaction with sequence-specific primers (PCR-SSP) or sequence-specific oligonucleotide probes (PCR-SSOP) and direct sequence-based typing (SBT). The main advantages of PCR-SSP and PCR-SSOP methods are that these methods are fast, generating useful data for discriminating the alleles of a small family. 8 However, the dependence on certain polymorphic sites for each allele or allele group identification confines these primer-or probe-based methods to low or intermediate resolutions when applied to studies of large allele families. 9 In contrast, SBT technology detects the polymorphic regions from conserved priming sites through direct sequencing, facilitating both high throughput and high resolution, and presenting a powerful technique for new allele identification. However, the main drawback of SBT is the ambiguities resulting from the cis/trans assignment of base calls in heterozygous samples. 9 One technical approach to the issue of ambiguity is to harness the power of next-generation sequencing methods; 9, 10 however, this option is an expensive choice for routine work.
In the case of A*02 subtyping, a number of methods have been established based on PCR-SSP [11] [12] [13] or PCR-SSOP.
set up a system with a large number of overlapping primers or probes and an even larger number of reactions or hybridizations to completely analyze each sample. The rapid growth in allele number reflects an even more rapid growth in the complexity of allele ambiguities in direct SBT. 2 To generate a simple and accurate method for subtyping A*02 alleles, we developed a strategy combining group-specific amplification and monoallelic sequencing to analyze all reported congenetic human MHC class I alleles. After validating this technique using a panel of reference samples, we successfully applied this scheme in another study to screen individuals of particular A*02 subtypes.
MATERIALS AND METHODS

Bioinformatics analysis
Multiple alignment files (in MSF format) of genomic and coding DNA sequences of MHC class I loci (HLA-A, -B, -C, -E, -F, -G, -H, -J, -K and -L) were downloaded from the FTP directory of the IMGT/HLA database (ftp://ftp.ebi.ac.uk/pub/databases/ ipd/imgt/hla/, release 3.12.0) and analyzed using ClustalX software (http://www.clustal.org/download/, version 2.1). A phylogenetic tree was generated using the program package PHYLIP (http://evolution.genetics.washington.edu/phylip.html, version 3.69), employing the neighbor-joining algorithm. The tree was viewed using FigTree software (http://tree.bio.ed.ac.uk/ software/figtree/, version 1.4.0). (Table 1) . A random population of 126 healthy Chinese individuals in Shanghai was enrolled in this study. The genomic DNA was prepared from the peripheral blood mononuclear cells of volunteers using a simple and reliable procedure (Supplementary Protocol 1) . Briefly, the cells were resuspended at 5310 3 cells/ml in 10 mM Tris-HCl (pH 8.0) containing 100 ng/ml proteinase K (Merck, Darmstadt, Germany) and heated at 56 uC for 1 h, followed by incubation at 95 uC for 10 min on a thermocycler.
Ethics statement
Primers, reaction combinations and amplification conditions Primers and related information are listed in Table 2 . The references are indicated for primers that have been previously described. The reaction combinations and related information are detailed in Table 3 . An internal control reaction, specific for a 333-bp region of the B2M gene, was included in each reaction in main-and sub-screening to verify that the PCR reaction functioned properly.
The 100-ml PCR reaction mixture contained 10 mM TrisHCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 mM of each dNTP, 0.2 mM of each primer, 2.5 units Taq DNA Polymerase Hot Start Version (TaKaRa, Dalian, China) and 10 ml template DNA. The template DNA was either 25 ng/ml purified genomic DNA or 5310 3 cells/ml lysates for reactions using cycling protocol CP1 (below) or 1 : 200 diluted CP1 products for the CP2 (below) reactions. The reaction volumes were 10 ml for screening and 50 ml for sequencing or cloning.
The PCR reactions were performed on a TProfessional Thermocycler (Biometra, Göttingen, Germany). The following cycling protocols were used: CP1: 95 uC 5 min, 5 cycles of (95 uC 1 min, 68 uC 1 min, 72 uC t E ), 5 cycles of (95 uC 1 min, 63 uC 1 min, 72 uC t E ), 25 cycles of (95 uC 30 s, 58 uC 45 s, 72 uC t E ) and 72 uC 5 min; and CP2: 95 uC 2 min, 5 cycles of (95 uC 30 s, 70 uC 1 min, 72 uC t E ), 5 cycles of (95 uC 30 s, 65 uC 1 min, 72 uC t E ), 10 cycles of (95 uC 30 s, 60 uC 45 s, 72 uC t E ) and 72 uC 5 min; where t E represents elongation time, as indicated with each reaction set listed in Table 3 . The PCR products (5 ml each sample) were analyzed on a 1% agarose gel stained with ethidium bromide.
Amplicon purification, sequencing and allele assignment The PCR amplicons were purified using the Cycle-Pure Kit (Omega Bio-Tek, Norcross, GA, USA) for direct sequencing, or using a cloning-sequencing strategy, the purified amplicons Table 2 . b Group names are specified in Figure 1 and were cloned into a pMD19-T vector (TaKaRa, Dalian, China), and the colony PCR products of two separate clones and of the original amplicons were subjected to sequencing. The allele assignment was accomplished through a nucleotide BLAST search in the IMGT/HLA database 2 using the combined sequences of exons 2-3 or 2-4 from the sequencing results.
RESULTS
Bioinformatics analysis and scheme design: mono-allelic sequencing based on group-specific amplification To design a scheme for subtyping A*02 alleles, we first analyzed the nucleotide sequences of the 540 reported A*02 alleles. A multiple alignment of the sequences of exons 2 and 3 was performed using ClustalX, and a phylogenetic tree was generated (Supplementary Figure 1) . We observed 197 parallel branches originating from the common allele group A*02:01:01G, implying the independent evolution of these latter alleles/groups. As it is impractical to determine numerous alleles/groups using conventional primer-or probe-based methods, such as PCR-SSP and PCR-SSOP, we employed another commonly used technology, SBT. However, when direct SBT is employed to analyze heterozygous samples, a large number of ambiguous allele combinations result, reflecting the similarities among A*02 alleles. Indeed, there are 17 235 ambiguous combinations containing A*02 alleles. 2 Because the major proportion of A*02 1 individuals are heterozygous for A*02 alleles, 16 we employed mono-allelic sequencing followed by the specific-amplification of A*02 alleles to overcome the ambiguity in direct SBT. The sequences of all 540 A*02 alleles were analyzed in the context of all alleles reported in both HLA-A and other congenetic MHC class I loci. Intriguingly, a single nucleotide alteration (from C to T at position 78), which distinguishes most A*02 alleles from others, was observed at the 59-end of exon 2, and this feature is relatively conserved among all class I alleles analyzed (Table 4 ). This feature was explored as a general rule for discrimination between A*02 and non-A*02 alleles through group-specific amplification using reactions 78C/I3 and 78T/I3 (Table 3) . For further discrimination of specific alleles outside the general grouping rule, group-or allele-specific reactions 77G/538A, 318A/555A, 149C/ 440G and 412A/555G (Table 3) were designed based on sequence analysis. Thus, we developed a simple scheme for the complete screening of A*02 alleles through group-specific amplification in haploid genomes (Figure 1) .
Next, we applied this screening scheme to diploid genomes, and subtyping strategies were developed for each case ( Table 5) (Table 3) using Seq-I1-RV is required to resolve this ambiguity. Figure 1 The scheme for full screening of HLA-A*02 alleles from haploid genomes using group-specific amplification. In Main-screening1, the reactions 78C/I3 and 78T/I3 amplify HLA-A alleles of General Non-A*02 (GNA2) and General A*02 (GA2) groups, respectively; the remaining HLA-A alleles are grouped as Special HLA-A (SA), in which reaction 77G/538A discriminates A*02:236 from Exceptional Non-A*02 (ENA2) alleles through Main-screening2. Reaction 318A/555A discriminates Special A*02 (SA2) alleles from Non-A*02 (NA2) alleles in GNA2 group through Sub-screening1, and either 149C/440G or 412A/555G or both reactions indicate the presence of Special Non-A*02 (SNA2) other than A*02 (A2) alleles in the GA2 group via Sub-screening2. The reactions are detailed in Table 3. 2. In case 3, the cloning-sequencing strategy is currently the most practical method to obtain accurate results, as there are still 1588 ambiguous combinations within these 533 A2 alleles; 2 for the rare case 2.2, we prefer the cloningsequencing strategy, instead of setting up a PCR-SSP system, for the identification of each SA2 allele. 3. In cases 3 and 2.2, amplicons from the diploid template and the colony PCR products of two separate clones were sequenced to reveal sequences on both haplotypes, facilitating corrections of possible PCR errors in some clones. 4. Table 5 represents a full scheme, which can be simplified according to the purpose of a given study. For example, in a common case where individuals of certain subtypes in GA2 group are screened and subtyped, one might screen for samples of cases 1 and 3 and treat case 1 as case 1.1 directly, considering that alleles of SA2 and SNA2 groups are rare.
Validation of the scheme with reference samples This scheme was validated through the screening and subtyping of a panel of reference samples of known HLA-A types obtained from the Fred Hutchinson Cancer Research Center IHWG Cell and Gene Bank. The screening/grouping results of the group-specific amplification of all samples were consistent with the HLA-A genotypes indicated in the database (Table 1) . Representative results are shown in Figure 2 .
The subtyping results of the mono-allelic sequencing of all A*02 1 samples were identical (or of higher resolutions) to the known identified A*02 subtypes, as indicated in the database. However, one exception, IHW09064, was detected in two separate experiments to be A*02:17:02 (Table 1) other than A*02:17:01 as reported. 17 These two alleles differ from each other in only one nucleotide in exon 1. 18 We searched for reports on the A*02:17:01 allele and found no additional confirmation of this polymorphic position, except for the initial report identifying this allele in the cell line AMALA (i.e., IHW09064). 17 Therefore, we consider that further confirmation of this allele in A*02:17:01 1 reference cell lines is needed.
Due to the lack of reference samples for A*02:236, SA2 or SNA2 subtypes, we analyzed each of these alleles/groups based on the parental groups defined in this study, and we generated a panel of substitution templates from the reference samples (Supplementary Table 1 and Supplementary Figure 2a) . These substitution templates consist of specific templates and most alike templates. The specific templates are of identical sequences at both priming sites to that of corresponding primers, respectively. Whereas most alike templates are of mismatched but most alike sequences at either priming site to that of the corresponding primer. The specificities of these primer sets were subsequently validated using these substitution templates (Supplementary Figure 2b) .
Screening and subtyping of the HLA-A*02 alleles in a random population in Shanghai We subsequently applied this scheme to the molecular screening and subtyping of A*02 alleles in a random Chinese population in Shanghai. The scheme yielded accurate subtyping results for each sample tested. Among the 126 individuals involved, 65 (51.6%) individuals were heterozygous and 11 (8.7%) individuals were homozygous for A*02. Among these 87 A*02 alleles, the top three frequent subtypes were A*02:01:01:01 (44.8%), A*02:07:01 (25.3%) and A*02:06:01 (16.1%).
DISCUSSION
In this study, we designed and validated a simple scheme for the complete screening and accurate subtyping of A*02 Table 4 MHC class I alleles sorted according to the nucleotide sequences at the 59-end of exon 2 alleles. This scheme was based on the observation that a single nucleotide alteration near the 59-end of exon 2 distinguishes most A*02 alleles from other MHC class I alleles. The group-specific amplification of 'general' A*02 or non-A*02 HLA-A alleles was achieved through specific priming at this polymorphic residue and a locus-specific site using an amplification refractory mutation system. Special alleles outside the general grouping rule were further discriminated through additional group-or allele-specific amplifications based on sequence analysis to completely screen all of the A*02 alleles reported to date.
We noted that the polymorphic residue mentioned has been widely explored for the specific amplification of A*02 alleles; 11, 12, [19] [20] [21] [22] however, only 14-37 A*02 alleles were identified at those times, and the number of non-A*02 alleles was small. In this study, through the complete analysis of all 7071 reported congenetic MHC class I alleles, we validated this feature as a general rule for A*02 and non-A*02 discrimination. For some special alleles reported, a small number of additional reactions were designed as patches for the general rule. We predict that as more alleles are identified, only some modifications in these patches will be needed to maintain the relevance of the current scheme.
Importantly, the differential amplification of A*02 and non-A*02 HLA-A alleles discriminates A*02 heterozygous individuals from homozygous individuals in diploid genomic samples and facilitates accurate subtyping using mono-allelic sequencing in heterozygous samples. Because most A*02 1 individuals are heterozygous for the A*02 allele, this scheme is highly efficient in the majority of cases. For A*02 homozygous samples, we suggest that the cloning-sequencing strategy is currently the most practical method for accurate subtyping. Compared with conventional procedures, 23 a minor modification was made in our cloning-sequencing strategy, sequencing colony PCR products, instead of amplicons or plasmid preparations from liquid cultures, which only required one more day than direct mono-allelic sequencing with heterozygous samples. Table 3 . b Group names are specified in Figure 1 and Table 4 . DNA sequencing has currently become a routine technique that is available and affordable in-house or from technical service companies. Therefore, the sequencing-based scheme designed in this study provides a feasible method for accurate A*02 subtyping in routine labs lacking sophisticated platforms, such as in HLA labs. Considering the prevalence and significance of A*02 alleles in the design of vaccines and in the development of disease treatments as well as the structural and functional differences between different subtypes, this simple subtyping scheme might be valuable for facilitating basic and clinical studies with interests in HLA-A*02. Table 3 , and the treatment strategies are outlined in Table 5 .
Representative results of three independent experiments.
